Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-1 (IGF-1) given peripherally has been found effective in clinical trials to slow down neuronal degeneration in some nervous system diseases. This raises the question of whether and how IGF-1 crosses the blood-brain barrier (BBB). In this report, we found that IGF-1 had a half-life of 4.5 min in blood, could remain intact for 20 min, and entered brain and spinal cord linearly. In the brain, IGF-1 had an influx rate of 0.4 µl/g·min after intravenous (iv) bolus injection as determined by multiple-time regression analysis. Intact radiolabeled IGF-1 was present in brain at 20 min after iv injection. Most of the injected IGF-1 entered the brain parenchyma instead of being entrapped in the cerebral vasculature. Addition of nonradiolabeled IGF-1 enhanced the influx of radiolabeled IGF-1 after iv injection, but inhibited the influx of radiolabeled IGF-1 by in-situ brain perfusion, suggesting that protein binding can explain the difference between the iv and perfusion experiments. In the spinal cord, the cervical region had the fastest uptake, followed by lumbar spinal cord. The thoracic spinal cord had the slowest uptake, comparable to that of brain. By contrast, des(1-3)IGF-1, an IGF-1 analogue with little protein binding but similar biological activity, had a shorter half-life in blood, slower influx rate into brain, and no alteration in pharmacokinetics after addition of nonradiolabeled peptide. We conclude that IGF-1 enters the CNS by a saturable transport system at the BBB, which functions in synchrony with IGF binding proteins in the periphery to regulate the availability of IGF-1 to the CNS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, since IGF-1 can readily pass the blood-brain barrier (Pan and Kastin 2000) in contrast to BDNF, its effects on the brain can be achieved by direct injection into the blood.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Pan and Kastin 2000
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Poduslo, J. F., & Curran, G. L. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00250-v · Cited by 614
Insulin-like growth factors cross the blood-brain barrier
Reinhardt, R., & Bondy, C. A. (1994) · Endocrinology · doi:10.1210/en.135.5.1753 · Cited by 391
Lai, E. C., Felice, K. J., Festoff, B. W., Gawel, M. J., Gelinas, D. F., Kratz, R., Murphy, M. F., Natter, H. M., Norris, F. H., Rudnicki, S. A., et al. (1997) · Neurology · doi:10.1212/wnl.49.6.1621 · Cited by 361
Insulin-Like Growth Factor Binding Proteins in the Human Circulation: A Review
Baxter, R. C. (1994) · Hormone Research · doi:10.1159/000184186 · Cited by 345
Permeability of the blood–brain barrier to neurotrophins
Pan, W., Banks, W. A., & Kastin, A. J. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01525-4 · Cited by 181
Self-citation(1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01036-3 · Cited by 177
Insulin-like Growth Factor-I: Potential for Treatment of Motor Neuronal Disorders
Lewis, M. E., Neff, N. T., Contreras, P. C., Stong, D. B., Oppenheim, R. W., Grebow, P. E., & Vaught, J. L. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1177 · Cited by 169
Human blood-brain barrier insulin-like growth factor receptor
Duffy, K. R., Pardridge, W. M., & Rosenfeld, R. G. (1988) · Metabolism · doi:10.1016/s0026-0495(98)90007-5 · Cited by 158
Passage of peptides across the blood-brain barrier: Pathophysiological perspectives
Banks, W. A., & Kastin, A. J. (1996) · Life Sciences · doi:10.1016/s0024-3205(96)00380-3 · Cited by 120
Self-citation
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
Lichtenwalner, R. J., Forbes, M. E., Bennett, S. A., Lynch, C. D., Sonntag, W. E., & Riddle, D. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00378-5 · Cited by 428
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Metadata
- Authors
- Pan, W., & Kastin, A. J.
- Affiliations
- Tulane University (US)
- ORCID
- Pan, Weihong
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2000
- Volume
- 72
- Issue
- 3
- Pages
- 171-178
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2093730240
- Cited by
- 185
- References
- 24
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 29 · 2023: 13 · 2022: 7 · 2021: 4 · 2020: 10 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 2 · 2014: 6 · 2013: 11 · 2012: 9
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuroendocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-54880)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- insulin-like growth factor I, blood-brain barrier, IGF binding proteins, protein binding, saturable transport, neuroprotection
- MeSH terms
- Animals, Biological Transport, Blood Chemical Analysis, Blood Circulation Time, Blood-Brain Barrier, Brain, Carrier Proteins, Cerebrovascular Circulation, Chromatography, High Pressure Liquid, Insulin-Like Growth Factor I, Iodine Radioisotopes, Male, Mice, Inbred ICR, Peptide Fragments, Radionuclide Imaging, Regression Analysis, Spinal Cord, Neurodegenerative Diseases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ. https://app.cochat.ai/papers/10.1159/000054584
- The paper
- Pan, W., & Kastin, A. J. (2000). Interactions of IGF-1 with the Blood-Brain Barrier in vivo and in situ. Neuroendocrinology. https://doi.org/10.1159/000054584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.